Saxagliptin helps to control blood sugar levels by increasing substances in the body that make the pancreas release more insulin. It also signals the liver to stop producing sugar (glucose) when there is too much sugar in the blood. Technically, saxagliptin is a selective dipeptidyl peptidase 4 inhibitor that prolongs the activity of endogenous incretin hormones, principally GLP-1 and GIP, producing glucose dependent increases in insulin secretion and decreases in glucagon release; it is orally active with rapid absorption (time to peak plasma concentration about two hours) and undergoes hepatic metabolism primarily via CYP3A4/5 to an active 5-hydroxy metabolite, with the parent compound and metabolite contributing to sustained DPP-4 inhibition that supports once daily dosing; key formulation and quality considerations include chemical stability, polymorphism, hygroscopicity and control of residual solvents and metal impurities during manufacturing.
Parent: Saxagliptin
Parent: Saxagliptin
Parent: Saxagliptin
Parent: Saxagliptin
Parent: Saxagliptin
![(1R,5R)-2-((2R)-2-Amino-2-(3-hydroxyadamantan-1-yl)acetyl)-2-azabicyclo[3.1.0]hexane-3-carbonitrile hydrochloride](https://veeprho.com/wp-content/uploads/2024/10/VE0022061-1R-5R-2-2R-2-Amino-2-3-hydroxyadamantan-1-yl.png "(1R,5R)-2-((2R)-2-Amino-2-(3-hydroxyadamantan-1-yl)acetyl)-2-azabicyclo[3.1.0]hexane-3-carbonitrile hydrochloride")
Parent: Saxagliptin
![(1S,3S,5S)-2-((S)-2-amino-2-((1r,3R,5R,7S)-3-hydroxyadamantan-1-yl)acetyl)-2-azabicyclo[3.1.0]hexane-3-carboxylic Acid](https://veeprho.com/wp-content/uploads/2022/07/1S-3S-5S-2-S-2-amino-2-1r-3R-5R-7S-3-hydroxyadamantan-1-ylacetyl-2-azabicyclo5B3.1.05Dhexane-3-carboxylic-Acid.png "(1S,3S,5S)-2-((S)-2-amino-2-((1r,3R,5R,7S)-3-hydroxyadamantan-1-yl)acetyl)-2-azabicyclo[3.1.0]hexane-3-carboxylic Acid")
Parent: Saxagliptin
![(1S,3S,5S)-2-azabicyclo[3.1.0]hexane-3-carbonitrile](https://veeprho.com/wp-content/uploads/2022/07/1S3S5S-2-azabicyclo3.1.0hexane-3-carbonitrile-1.png "(1S,3S,5S)-2-azabicyclo[3.1.0]hexane-3-carbonitrile")
Parent: Saxagliptin
![(1S,3S,5S)-2-Azabicyclo[3.1.0]hexane-3-carboxamide methanesulfonate](https://veeprho.com/wp-content/uploads/2026/01/1S3S5S-2-Azabicyclo3.1.0hexane-3-carboxamide-methanesulfonate-709031-45-8-VE0026164-296b.png "(1S,3S,5S)-2-Azabicyclo[3.1.0]hexane-3-carboxamide methanesulfonate")
Parent: Saxagliptin
Parent: Saxagliptin
The impurity profile of saxagliptin drug substance and finished product typically includes process-related and degradation related compounds such as N-oxide derivatives, hydroxylated and dealkylated species, des-cyclopropyl analogs, ring-opened products, trace starting materials and residual solvents; manufacturers and regulators set quantitative limits that reflect identification, qualification and safety requirements, with common internal control ranges for specified related substances often in the 0.05 to 0.5 percent range for individual impurities and a typical total related substances limit in the 0.5 to 1.0 percent range depending on the impurity toxicology and maximum daily dose, while reporting thresholds for unknowns are frequently set around 0.05 to 0.10 percent and residual solvents and elemental impurities are controlled per ICH Q3C and Q3D guidance.
Saxagliptin is used as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus, either as monotherapy or in combination with other antihyperglycemic agents as determined by a clinician.
No, saxagliptin and Januvia are different chemical entities; Januvia is the brand name for sitagliptin, while saxagliptin is a separate DPP-4 inhibitor with distinct pharmacokinetics and metabolic pathways.
No, saxagliptin is not a GLP-1 receptor agonist; it is a DPP-4 enzyme inhibitor that increases endogenous GLP-1 and GIP levels by preventing their enzymatic degradation.
Both sitagliptin and saxagliptin are DPP-4 inhibitors with broadly similar glucose lowering efficacy, but differences in metabolism, drug interactions, dosing considerations and safety signals mean that choice depends on individual patient factors such as renal function, concomitant medications and cardiovascular history and should be made by a healthcare professional.
